These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7604818)

  • 41. Age as a risk factor for myocardial infarction in Leiden mutation carriers.
    Baranovskaya S; Kudinov S; Fomicheva E; Vasina V; Solovieva D; Khavinson V; Schwartz E
    Mol Genet Metab; 1998 Jun; 64(2):155-7. PubMed ID: 9705241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Recently discovered frequent cause of venous thrombosis: factor V Leiden, a mutated factor V, resistant against protein C inactivation].
    Rosendaal FR
    Ned Tijdschr Geneeskd; 1994 Sep; 138(39):1944-8. PubMed ID: 7935943
    [No Abstract]   [Full Text] [Related]  

  • 45. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene.
    Dahlbäck B
    Haemostasis; 1994; 24(2):139-51. PubMed ID: 7959362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome.
    Dizon-Townson D; Hutchison C; Silver R; Branch DW; Ward K
    Thromb Haemost; 1995 Oct; 74(4):1029-31. PubMed ID: 8560406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenotyping and genotyping of coagulation factor V Leiden.
    Engel H; Zwang L; van Vliet HH; Michiels JJ; Stibbe J; Lindemans J
    Thromb Haemost; 1996 Feb; 75(2):267-9. PubMed ID: 8815574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
    Mandel H; Brenner B; Berant M; Rosenberg N; Lanir N; Jakobs C; Fowler B; Seligsohn U
    N Engl J Med; 1996 Mar; 334(12):763-8. PubMed ID: 8592550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis.
    Bertina RM; Reitsma PH; Rosendaal FR; Vandenbroucke JP
    Thromb Haemost; 1995 Jul; 74(1):449-53. PubMed ID: 8578504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
    Price DT; Ridker PM
    Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
    Tosetto A; Missiaglia E; Gatto E; Rodeghiero F
    Thromb Haemost; 1997 Aug; 78(2):859-63. PubMed ID: 9268185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
    Dahlbäck B; Zöller B; Hillarp A
    Haemostasis; 1996 Oct; 26 Suppl 4():301-14. PubMed ID: 8979136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation.
    Simioni P; Scarano L; Gavasso S; Sardella C; Girolami B; Scudeller A; Girolami A
    Br J Haematol; 1996 Feb; 92(2):435-41. PubMed ID: 8603014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia.
    Lee DH; Warkentin TE; Denomme GA; Lagrotteria DD; Kelton JG
    Thromb Haemost; 1998 Jan; 79(1):50-3. PubMed ID: 9459322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers.
    Grossman D; Heald PW; Wang C; Rinder HM
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):409-13. PubMed ID: 9308555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factor V Leiden-dependent APC resistance: improved sensitivity and specificity of the APC resistance test by plasma dilution in factor V-depleted plasma.
    Gouault-Heilmann M; Leroy-Matheron C
    Thromb Res; 1996 May; 82(3):281-3. PubMed ID: 8732632
    [No Abstract]   [Full Text] [Related]  

  • 58. Resistance to activated protein C and a novel factor V gene mutation.
    Voelkerding KV
    Clin Lab Med; 1996 Mar; 16(1):169-86. PubMed ID: 8867589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence of factor V Leiden (1691 G-->A) mutation in Turkey.
    Gürgey A; Mesci L
    Turk J Pediatr; 1997; 39(3):313-5. PubMed ID: 9339109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
    Weitz IC; Israel VK; Liebman HA
    Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.